GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B2242 Urapidil HClSummary: α1-adrenoceptor antagonist and 5-HT1A receptor agonist -
B2264 Dapoxetine HClSummary: Selective serotonin reuptake inhibitor -
B1687 Buspirone HClSummary: Classic 5-HT1A partial agonist -
B2248 Ketanserin4 CitationTarget: 5-HT2 ReceptorsSummary: specific 5-HT2A serotonin receptor antagonist -
B1354 Bisoprolol fumarateSummary: Selective α-adrenergic blocker -
B1362 NaftopidilSummary: α1-adrenergic receptor antagonist -
B2009 PranlukastSummary: selective antagonist of the cysteinyl leukotrienes (LT) C(4), LTD(4) and LTE(4), -
B1740 EbastineSummary: Histamine receptor antagonist -
B2203 Candesartan CilexetilTarget: Angiotensin AT2 ReceptorsSummary: Prodrug of the angiotensin II receptor 1 (AT1) antagonist candesartan -
B1355 Cisatracurium BesylateTarget: AcetylcholineSummary: Neuromuscular-blocking drug

